Amneal Pharmaceuticals (NASDAQ:AMRX) Announces Quarterly Earnings Results

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) posted its earnings results on Friday. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03), RTT News reports. The firm had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter last year, the company posted $0.14 EPS. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.700 EPS.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock traded up $0.13 during trading on Wednesday, hitting $8.97. The stock had a trading volume of 2,283,639 shares, compared to its average volume of 1,385,344. The business has a fifty day moving average of $8.14 and a two-hundred day moving average of $8.33. Amneal Pharmaceuticals has a fifty-two week low of $5.18 and a fifty-two week high of $9.48. The firm has a market cap of $2.78 billion, a P/E ratio of -13.19 and a beta of 1.10.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the transaction, the director now owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. The trade was a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 160,000 shares of company stock valued at $1,292,000 over the last three months. Company insiders own 26.56% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several analysts recently commented on AMRX shares. StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Piper Sandler raised their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, November 11th. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $10.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.